» Articles » PMID: 37031335

Hsa_circITGA4/ MiR-1468/EGFR/ PTEN a Master Regulators Axis in Glioblastoma Development and Progression

Overview
Journal Mol Biotechnol
Publisher Springer
Date 2023 Apr 8
PMID 37031335
Authors
Affiliations
Soon will be listed here.
Abstract

In the fight against glioblastoma, circular RNA is emerging as a functional molecule. However, how circular RNA (circRNA) is regulated and what role it plays is still a mystery. In this research, different bioinformatics approaches were used to evaluate glioblastoma circRNA sequencing and array data, with the goal of developing a putative molecular sponge mechanism control network. The circRNAs were obtained from the Gene Expression Omnibus datasets. MicroRNA-circRNA interactions were predicted using CircInteractome. The microRNAs' expression and survival trends were screened using the TCGA database. MicroRNA gene targets were predicted using the MiRnet database. Sponge network gene candidates were screened using data from the GEPIA. The roles of the targeted genes were to be explained by analyzing data from Gene Ontology and the Kyoto Encyclopedia of Genes and Genomes. To build the network and display the outcomes, we utilized python program, and enrichment online Bioinformatics databases. The circRNAs hsa_circITGA4_002, hsa_circITGA4_001, hsa_circITGA4_003, hsa_circ_0030855, hsa_circ_0030857 were chosen from among GBM patients and control group. Upregulation of hsa-miR-1468, hsa-miR-3683, hsa-miR-1273c, and hsa-miR-4665-3p were associated with a poor prognosis in GBM. MicroRNA targets such as ITGA4, LAMA2, EGFR, PTEN, COL1A4, and NCAM2 were analyzed using expression and survival data. The Apoptosis, cell adhesion molecules, PI3K/AKT and P53 signaling pathways were the most abundant functional categories among gene targets. The circRNA molecular sponge regulatory network includes hsa-miR-1468 and hsa-miR-4665-3p. In this network, hs hsa_circITGA4_002, hsa_circITGA4_001, hsa_circ_0030857, EGFR, PTEN, and ITGA4 may represent GBM therapeutic targets. Their role in GBM needs additional study.

Citing Articles

ITGA4 as a potential prognostic and immunotherapeutic biomarker in human cancer and its clinical significance in gastric cancer: an integrated analysis and validation.

Zhang J, Wang G, Liu J, Tang F, Wang S, Li Y Front Oncol. 2025; 15:1513622.

PMID: 40012546 PMC: 11860100. DOI: 10.3389/fonc.2025.1513622.

References
1.
Kaptein F, Stals M, Kapteijn M, Cannegieter S, Dirven L, van Duinen S . Incidence and determinants of thrombotic and bleeding complications in patients with glioblastoma. J Thromb Haemost. 2022; 20(7):1665-1673. PMC: 9320838. DOI: 10.1111/jth.15739. View

2.
Tan A, Ashley D, Lopez G, Malinzak M, Friedman H, Khasraw M . Management of glioblastoma: State of the art and future directions. CA Cancer J Clin. 2020; 70(4):299-312. DOI: 10.3322/caac.21613. View

3.
Wen P, Weller M, Quant Lee E, Alexander B, Barnholtz-Sloan J, Barthel F . Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions. Neuro Oncol. 2020; 22(8):1073-1113. PMC: 7594557. DOI: 10.1093/neuonc/noaa106. View

4.
Bahadur S, Sahu A, Baghel P, Saha S . Current promising treatment strategy for glioblastoma multiform: A review. Oncol Rev. 2019; 13(2):417. PMC: 6661528. DOI: 10.4081/oncol.2019.417. View

5.
Sanders S, Debinski W . Challenges to Successful Implementation of the Immune Checkpoint Inhibitors for Treatment of Glioblastoma. Int J Mol Sci. 2020; 21(8). PMC: 7215941. DOI: 10.3390/ijms21082759. View